Venous thrombosis and hormonal contraception: what's new with estradiol-based hormonal contraceptives?
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Estradiol (E2)-based hormonal contraceptives impact less than ethinylstradiol (EE) contraceptives on venous thromboembolism (VTE) in comparison to formulations with EE. STUDY DESIGN: In this article, the pharamacologic data of EE and E2 were briefly reviewed, along with the induced biologic effect. These data were then related to a recent large international prospective, controlled, non-interventional cohort active surveillance study, on the cardiovascular risk of users of different types of combined estroprogestin contraceptive (CEPC). RESULTS: The crude HR for E2-valerate (E2V)/dienogest vs other CEPCs with EE was 0.8 (95% CI, 0.4-1.6), but when the data were corrected for age, body mass index, duration of use, and family history of VTE, the corresponding adjusted HR was 0.5 (95% CI, 0.2-1.0). A comparison of the E2V/dienogest and EE/levonorgestrel groups showed that the two contraceptives induced a similar VTE risk with the crude and adjusted VTE HRs of 0.7 (95% CI, 0.3-1.8) and 0.5 (95% CI, 0.2-1.3), respectively. Similar results were obtained when the observation was prolonged to January 2017. CONCLUSIONS: The reduced impact of E2 vs EE on coagulation translates into the epidemiologic evidence of a reduced number of events in E2V vs EE users, when progestins other than levonorgestrel are used. However, E2 may continue to negatively impact on the risk of VTE, and this should not be forgotten at the time of prescription. Family history of VTE or thrombophilia, age, and obesity are risk factors for VTE too. If these risk factors are not taken into consideration and excluded, they can overcome or hide the higher safety of E2 vs CEPCs with EE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hormonal contraception and risk of venous thromboembolism: national follow-up study
Lidegaard, O., Lokkegaard, E., Svendsen, A. L., & Agger, C. (2009) · BMJ · doi:10.1136/bmj.b2890 · Cited by 709
Lidegaard, O., Nielsen, L. H., Skovlund, C. W., Skjeldestad, F. E., & Lokkegaard, E. (2011) · BMJ · doi:10.1136/bmj.d6423 · Cited by 608
Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10
Lidegaard, O., Nielsen, L. H., Skovlund, C. W., & Lokkegaard, E. (2012) · BMJ · doi:10.1136/bmj.e2990 · Cited by 326
Dragoman, M. V., Tepper, N. K., Fu, R., Curtis, K. M., Chou, R., & Gaffield, M. E. (2018) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.12455 · Cited by 253 · cited 1×
“Oral and nonoral estro-progestin combined contraceptives (CEPC) increase the risk of VTE, including deep venous thromboembolism and pulmonary embolism (PE).(2,3) The risk is low (less than 5–12 events per 10,000 women-years of exposure) and lower than the VTE risk observed during pregnancy and in the postpartum period.”
Impact of estrogen type on cardiovascular safety of combined oral contraceptives
Dinger, J., Do Minh, T., & Heinemann, K. (2016) · Contraception · doi:10.1016/j.contraception.2016.06.010 · Cited by 160 · cited 7×
“Accordingly, CEPCs with E2 may significantly reduce the overall VTE burden linked to the use of contraception and be used in place of EE/levonorgestrel.”
InfluentialÅgren, U. M., Anttila, M., Mäenpää-Liukko, K., Rantala, M.-L., Rautiainen, H., Sommer, W. F., & Mommers, E. (2011) · The European Journal of Contraception & Reproductive Health Care · doi:10.3109/13625187.2011.604450 · Cited by 130
Junge, W., Mellinger, U., Parke, S., & Serrani, M. (2011) · Clinical Drug Investigation · doi:10.2165/11590220-000000000-00000 · Cited by 107
Cited by
Douxfils, J., Klipping, C., Duijkers, I., Kinet, V., Mawet, M., Maillard, C., Jost, M., Rosing, J., & Foidart, J.-M. (2020) · Contraception · doi:10.1016/j.contraception.2020.08.015 · Cited by 120
Systemic hormonal contraception and risk of venous thromboembolism
Heikinheimo, O., Toffol, E., Partonen, T., But, A., Latvala, A., & Haukka, J. (2022) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.14384 · Cited by 58
Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS
Cignarella, A., Mioni, R., Sabbadin, C., Dassie, F., Parolin, M., Vettor, R., Barbot, M., & Scaroni, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249554 · Cited by 36
A current perspective into young female sex hormone replacement: a review
Giordano Imbroll, M., & Gruppetta, M. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1816820 · Cited by 7
Metadata
- Authors
- Fruzzetti, F., & Cagnacci, A.
- Venue
- Open Access Journal of Contraception
- Publisher
- Informa UK Limited
- Published
- 2018-11
- Volume
- Volume 9
- Pages
- 75-79
- ISSN
- 1179-1527 (ISSN-L)
- OpenAlex
- W2901665003
- Cited by
- 59
- References
- 7
- FWCI
- 2.82
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.